{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurocutaneous+Syndromes&page=2",
    "query": {
      "condition": "Neurocutaneous Syndromes",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurocutaneous+Syndromes&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T05:44:06.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05059327",
      "title": "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex"
      ],
      "interventions": [
        {
          "name": "Basimglurant with crossover to Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo with crossover to Basimglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noema Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "5 Years to 30 Years"
      },
      "enrollment_count": 61,
      "start_date": "2022-03-03",
      "completion_date": "2025-04-28",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Roseville",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059327"
    },
    {
      "nct_id": "NCT05238909",
      "title": "Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis 1",
        "NF1",
        "Neurofibromatosis Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2022-03-04",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238909"
    },
    {
      "nct_id": "NCT00030043",
      "title": "An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis 2"
      ],
      "interventions": [
        {
          "name": "Penetrating auditory brainstem implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "FDA Office of Orphan Products Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2001-09",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Pasadena, California • Englewood, Colorado",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030043"
    },
    {
      "nct_id": "NCT06961565",
      "title": "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NF1 Mutation",
        "Neurofibroma Plexiform",
        "Neurofibroma, Plexiform",
        "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)",
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "PAS-004 Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pasithea Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-05-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06961565"
    },
    {
      "nct_id": "NCT04924075",
      "title": "Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pheochromocytoma/Paraganglioma",
        "Pancreatic Neuroendocrine Tumor",
        "Von Hippel-Lindau Disease",
        "Advanced Gastrointestinal Stromal Tumor",
        "HIF-2α Mutated Cancers"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2021-08-12",
      "completion_date": "2029-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924075"
    },
    {
      "nct_id": "NCT04947124",
      "title": "A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sturge-Weber Syndrome (SWS)",
        "Glaucoma",
        "Glaucoma Congenital",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "QLS-101ophthalmic solution 1%",
          "type": "DRUG"
        },
        {
          "name": "QLS-101ophthalmic solution 2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qlaris Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-10-19",
      "completion_date": "2022-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04947124"
    },
    {
      "nct_id": "NCT05849662",
      "title": "A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Juvenile Myelomonocytic",
        "JMML",
        "JCML",
        "Neurofibromatosis 1",
        "CBL Syndrome"
      ],
      "interventions": [
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Month to 21 Years"
      },
      "enrollment_count": 58,
      "start_date": "2024-10-11",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05849662"
    },
    {
      "nct_id": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PF-07284892",
          "type": "DRUG"
        },
        {
          "name": "lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "binimetinib",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "encorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2021-03-17",
      "completion_date": "2024-06-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04800822"
    },
    {
      "nct_id": "NCT05677594",
      "title": "Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis 1",
        "Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis)",
        "Atypical Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Whole Body Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-07-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05677594"
    },
    {
      "nct_id": "NCT03993821",
      "title": "Burosumab for CSHS",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)",
        "Epidermal Nevus Syndrome"
      ],
      "interventions": [
        {
          "name": "Burosumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laura Tosi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2019-07-01",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-06-10T05:44:06.639Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993821"
    }
  ]
}